Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 89 entries
View as:

A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector

Phase: N/A Priority: Normal
NCT ID: NCT06732973 Org: User:
Start: 12/20/24 End: 12/30/25 Due: 12/30/26

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06954467 Org: User:
Start: 05/26/25 End: 06/30/28 Due: 06/30/29

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05618327 Org: User:
Start: 02/13/23 End: 12/30/26 Due: 12/30/27

Clinical Study of JS007 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05049265 Org: User:
Start: 11/17/21 End: 09/20/22 Due: 09/20/23

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

Phase: N/A Priority: Normal
NCT ID: NCT06888830 Org: User:
Start: 04/11/25 End: 04/01/27 Due: 04/01/28

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04278859 Org: User:
Start: 04/28/20 End: 07/13/23 Due: 07/13/24

A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06868836 Org: User:
Start: 05/30/25 End: 04/30/27 Due: 04/30/28

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05657418 Org: User:
Start: 03/29/22 End: 01/04/25 Due: 01/04/26

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04568304 Org: User:
Start: 11/30/20 End: 11/30/25 Due: 11/30/26

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06944470 Org: User:
Start: 04/20/25 End: 12/31/27 Due: 12/31/28

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04158440 Org: User:
Start: 04/07/20 End: 12/31/25 Due: 12/31/26

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Phase: N/A Priority: Normal
NCT ID: NCT05621070 Org: User:
Start: 02/03/23 End: 09/30/24 Due: 09/30/25

A Pharmacokinetic Study of JS002 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05859529 Org: User:
Start: 05/30/23 End: 09/11/23 Due: 09/11/24

Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

Phase: N/A Priority: Normal
NCT ID: NCT04723004 Org: User:
Start: 10/15/20 End: 12/31/24 Due: 12/31/25

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05128539 Org: User:
Start: 02/10/22 End: 11/10/23 Due: 11/10/24

A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06158737 Org: User:
Start: 05/09/23 End: 09/21/24 Due: 09/21/25

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS

Phase: N/A Priority: Normal
NCT ID: NCT05212051 Org: User:
Start: 12/10/21 End: 01/11/23 Due: 01/11/24

JS001+IMP4297 in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05262842 Org: User:
Start: 03/29/22 End: 06/06/24 Due: 06/06/25

Study of JS001 in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02857166 Org: User:
Start: 03/31/16 End: 12/31/18 Due: 12/31/19

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03113266 Org: User:
Start: 04/06/17 End: 02/28/22 Due: 02/28/23

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

Phase: N/A Priority: Normal
NCT ID: NCT03859128 Org: User:
Start: 03/05/19 End: 08/01/23 Due: 08/01/24

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT04523493 Org: User:
Start: 06/29/20 End: 09/01/26 Due: 09/01/27

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Phase: N/A Priority: Normal
NCT ID: NCT04781114 Org: User:
Start: 12/23/20 End: 01/16/23 Due: 01/16/24

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04848753 Org: User:
Start: 06/23/21 End: 05/12/27 Due: 05/12/28

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03513666 Org: User:
Start: 04/09/18 End: 08/12/22 Due: 08/12/23